Nektar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 137
- Market Cap
- $230M
- Website
- http://www.nektar.com
- Introduction
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cance...
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 291
- Registration Number
- NCT04433585
- Locations
- 🇺🇸
Clinical Research Center of CT/NY, Danbury, Connecticut, United States
🇺🇸Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Northwell Health, Great Neck, New York, United States
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 765
- Registration Number
- NCT04410445
- Locations
- 🇺🇸
Department of Pharmacy Investigational Drug Services, Dallas, Texas, United States
🇺🇸Southern California Permanente Medical Group, Riverside, California, United States
🇺🇸Texas Oncology (Loop) - USOR, Dallas, Texas, United States
A Study of NKTR-358 (LY3471851) in Healthy Participants
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT04380324
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04136756
- Locations
- 🇺🇸
Western Regional Medical Center - CTCA, Goodyear, Arizona, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸New York Medical College, Valhalla, New York, United States
A Study of LY3471851 in Healthy Participants
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04133116
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
A Study of LY3471851 in Participants With Psoriasis
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04119557
- Locations
- 🇺🇸
Clinical Science Institute, Santa Monica, California, United States
🇺🇸Remington-Davis, Inc, Columbus, Ohio, United States
🇺🇸Paddington Testing Company Inc, Philadelphia, Pennsylvania, United States
A Study of LY3471851 in Participants With Eczema
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT04081350
- Locations
- 🇺🇸
Complete Dermatology, Sugar Land, Texas, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
🇺🇸Remington-Davis, Inc, Columbus, Ohio, United States
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03802227
- Locations
- 🇺🇸
Investigator Site - Richmond, Richmond, Virginia, United States
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 192
- Registration Number
- NCT03785925
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Pozuelo De Alarcón, Madrid, Spain
🇫🇷Centre François Baclesse, Caen, Calvados, France
🇬🇷Medical Center of Athens, Maroúsi, Attiki, Greece
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 623
- Registration Number
- NCT03729245
- Locations
- 🇺🇸
Alaska Urological, Anchorage, Alaska, United States
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States
🇦🇷Centro de Investigación Pergamino S.A, Buenos Aires, Argentina